Profitelligence Profitelligence · Filing Ledger Open ILMN research →

Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-05-28

Meister Keith A. Files Illumina (ILMN) Form 4 - May 28, 2026

Meister Keith A. traded 718.7K ILMN shares worth $113.4M in this Form 4 filing, reported to the SEC on 2026-05-28.

Issuer
Illumina, Inc. ILMN · NASDAQ
Filed
Period
2026-05-28
Accession
0001011438-26-000371

Transactions (19)

Insider Date Type Shares Price Value Own
Meister Keith A. 2026-06-01 Sell 15.5K $165.50 $2.6M Indirect
Meister Keith A. 2026-06-01 Sell 87.7K $164.34 $14.4M Indirect
Meister Keith A. 2026-06-01 Sell 61.6K $163.56 $10.1M Indirect
Meister Keith A. 2026-06-01 Sell 70.3K $162.41 $11.4M Indirect
Meister Keith A. 2026-05-29 Sell 2.2K $162.44 $361.4K Indirect
Meister Keith A. 2026-05-29 Sell 19.8K $163.57 $3.2M Indirect
Meister Keith A. 2026-05-29 Sell 11.8K $159.57 $1.9M Indirect
Meister Keith A. 2026-05-29 Sell 4.6K $160.50 $734.9K Indirect
Meister Keith A. 2026-05-29 Sell 5.3K $161.64 $849.6K Indirect
Meister Keith A. 2026-05-29 Sell 6.9K $164.75 $1.1M Indirect
Meister Keith A. 2026-05-29 Sell 63.0K $162.86 $10.3M Indirect
Meister Keith A. 2026-05-29 Sell 6.2K $163.97 $1.0M Indirect
Meister Keith A. 2026-05-29 Sell 92.9K $164.56 $15.3M Indirect
Meister Keith A. 2026-05-29 Sell 2.0K $165.30 $324.2K Indirect
Meister Keith A. 2026-05-28 Buy 24.6K $102.82 $2.5M Indirect
Meister Keith A. 2026-05-28 Sell 24.6K $156.40 $3.8M Indirect
Meister Keith A. 2026-05-28 Sell 110.4K $147.50 $16.3M Indirect
Meister Keith A. 2026-05-28 Sell 72.0K $157.38 $11.3M Indirect
Meister Keith A. 2026-05-28 Sell 37.6K $156.50 $5.9M Indirect
Net change−669.6K−$108.4M

About Illumina, Inc.

Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Track ILMN insider activity

Get alerted when Illumina, Inc. executives buy or sell their shares.

Set up free alerts